{"_id": "64fe7f991544b4d920499d0b", "nctID": "NCT02298959", "booleanRepresentation": "{\n    \"$and\": [\n        {\n            \"$or\": [\n                {\n                    \"$and\": [\n                        {\"$or\": [\n                            {\"histologically confirmed metastatic disease from any solid tumor (NOS 10029000)\"},\n                            {\"histologically confirmed metastatic melanoma (10053571)\"},\n                            {\"histologically confirmed renal cell carcinoma (NOS 10038485)\"},\n                            {\"histologically confirmed ovarian cancer (NOS 10033272)\"},\n                            {\"histologically confirmed colorectal cancer (10009951,10038045)\"},\n                            {\"histologically confirmed PD-1 resistant melanoma (10053571)\"},\n                            {\"histologically confirmed PD-1 resistant renal cancer (NOS 10038485)\"},\n                            {\"histologically confirmed sarcoma (10061271)\"}\n                        ]},\n                        {\"$or\": [\n                            {\"renal cell patients with at least one prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)\"},\n                            {\"ovarian cancer patients resistant to platinum therapy\"},\n                            {\"colorectal cancer patients who have failed at least one oxaliplatin-containing regimen\"}\n                        ]},\n                        {\"$or\": [\n                            {\"no more than two prior therapies for metastatic disease\"},\n                            {\"age greater than or equal to 18 years\"},\n                            {\"ECOG performance status less than or equal to 1 (Karnofsky greater than or equal to 70%)\"},\n                            {\"estimated life expectancy greater than 6 months\"},\n                            {\"leukocytes greater than or equal to 2,000/mcL (within 10 days of treatment initiation)\"},\n                            {\"absolute neutrophil count greater than or equal to 1,500/mcL (within 10 days of treatment initiation)\"},\n                            {\"platelets greater than or equal to 100,000/mcL (within 10 days of treatment initiation)\"},\n                            {\"hemoglobin greater than or equal to 9 g/dL OR greater than or equal to 5.6 mmol/L (within 10 days of treatment initiation)\"},\n                            {\"serum total bilirubin less than or equal to 1.5 X upper limit of normal (ULN) OR direct bilirubin less than or equal to ULN for patients with total bilirubin levels greater than 1.5 ULN (within 10 days of treatment initiation)\"},\n                            {\"aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 2.5 X institutional ULN OR less than or equal to 5 X ULN for patients with liver metastases (within 10 days of treatment initiation)\"},\n                            {\"serum creatinine less than or equal to 1.5 X ULN or measured or calculated creatinine clearance (CrCl) greater than or equal to 60 mL/min for subject with creatinine levels greater than 1.5 X institutional ULN (within 10 days of treatment initiation)\"},\n                            {\"international normalized ratio (INR) or prothrombin time (PT) less than or equal to 1.5 X ULN unless subject is receiving anticoagulant therapy not requiring laboratory monitoring as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants; therapeutic Coumadin is not acceptable (within 10 days of treatment initiation)\"},\n                            {\"activated partial thromboplastin time (aPTT) less than or equal to 1.5 X ULN unless subject is receiving anticoagulant therapy not requiring laboratory monitoring as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 10 days of treatment initiation)\"},\n                            {\"urine protein-creatinine ratio (UPCR) less than or equal to 1 on spot urinalysis or protein less than or equal to 500 mg/24 hour urine\"},\n                            {\"archival tissue must be available or newly obtained core or excisional biopsy of a tumor lesion\"},\n                            {\"measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"},\n                            {\"adequate contraception for women of child-bearing potential and men\"},\n                            {\"negative pregnancy test for female patients of childbearing potential\"},\n                            {\"willingness to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication for female patients of childbearing potential\"},\n                            {\"ability to understand and the willingness to sign a written informed consent document\"},\n                            {\"dose expansion part 2 PD-1/PD-L1 resistant or refractory melanoma and renal cell cancer only: subjects must have received prior immunotherapy with an anti-PD-1 or anti-PD-L1 containing regimen and must have progressive or recurrent disease after prior PD-1/PD-L1 directed therapy; primary resistance is determined at the time of initial restaging from initiation of treatment, as evidenced by progression by RECIST 1.1; acquired resistance would be a subject who had a best overall RECIST response of stable disease, partial response, or complete response confirmed radiographically by a second scan who subsequently developed progressive disease by RECIST 1.1 at any time thereafter\"},\n                            {\"dose expansion part 2 sarcoma only: subjects must have received standard of care treatment\"}\n                        ]}\n                    ]\n                },\n                {\n                    \"$and\": [\n                        {\"$or\": [\n                            {\"histologically confirmed metastatic disease from any solid tumor (NOS 10029000)\"},\n                            {\"histologically confirmed metastatic melanoma (10053571)\"},\n                            {\"histologically confirmed renal cell carcinoma (NOS 10038485)\"},\n                            {\"histologically confirmed ovarian cancer (NOS 10033272)\"},\n                            {\"histologically confirmed colorectal cancer (10009951,10038045)\"},\n                            {\"histologically confirmed PD-1 resistant melanoma (10053571)\"},\n                            {\"histologically confirmed PD-1 resistant renal cancer (NOS 10038485)\"},\n                            {\"histologically confirmed sarcoma (10061271)\"}\n                        ]},\n                        {\"$or\": [\n                            {\"renal cell patients with at least one prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)\"},\n                            {\"ovarian cancer patients resistant to platinum therapy\"},\n                            {\"colorectal cancer patients who have failed at least one oxaliplatin-containing regimen\"}\n                        ]},\n                        {\"$or\": [\n                            {\"no more than two prior therapies for metastatic disease\"},\n                            {\"age greater than or equal to 18 years\"},\n                            {\"ECOG performance status less than or equal to 1 (Karnofsky greater than or equal to 70%)\"},\n                            {\"estimated life expectancy greater than 6 months\"},\n                            {\"leukocytes greater than or equal to 2,000/mcL (within 10 days of treatment initiation)\"},\n                            {\"absolute neutrophil count greater than or equal to 1,500/mcL (within 10 days of treatment initiation)\"},\n                            {\"platelets greater than or equal to 100,000/mcL (within 10 days of treatment initiation)\"},\n                            {\"hemoglobin greater than or equal to 9 g/dL OR greater than or equal to 5.6 mmol/L (within 10 days of treatment initiation)\"},\n                            {\"serum total bilirubin less than or equal to 1.5 X upper limit of normal (ULN) OR direct bilirubin less than or equal to ULN for patients with total bilirubin levels greater than 1.5 ULN (within 10 days of treatment initiation)\"},\n                            {\"aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 2.5 X institutional ULN OR less than or equal to 5 X ULN for patients with liver metastases (within 10 days of treatment initiation)\"},\n                            {\"serum creatinine less than or equal to 1.5 X ULN or measured or calculated creatinine clearance (CrCl) greater than or equal to 60 mL/min for subject with creatinine levels greater than 1.5 X institutional ULN (within 10 days of treatment initiation)\"},\n                            {\"international normalized ratio (INR) or prothrombin time (PT) less than or equal to 1.5 X ULN unless subject is receiving anticoagulant therapy not requiring laboratory monitoring as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants; therapeutic Coumadin is not acceptable (within 10 days of treatment initiation)\"},\n                            {\"activated partial thromboplastin time (aPTT) less than or equal to 1.5 X ULN unless subject is receiving anticoagulant therapy not requiring laboratory monitoring as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 10 days of treatment initiation)\"},\n                            {\"urine protein-creatinine ratio (UPCR) less than or equal to 1 on spot urinalysis or protein less than or equal to 500 mg/24 hour urine\"},\n                            {\"archival tissue must be available or newly obtained core or excisional biopsy of a tumor lesion\"},\n                            {\"measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\"},\n                            {\"adequate contraception for women of child-bearing potential and men\"},\n                            {\"negative pregnancy test for female patients of childbearing potential\"},\n                            {\"willingness to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication for female patients of childbearing potential\"},\n                            {\"ability to understand and the willingness to sign a written informed consent document\"},\n                            {\"dose expansion part 2 PD-1/PD-L1 resistant or refractory melanoma and renal cell cancer only: subjects must have received prior immunotherapy with an anti-PD-1 or anti-PD-L1 containing regimen and must have progressive or recurrent disease after prior PD-1/PD-L1 directed therapy; primary resistance is determined at the time of initial restaging from initiation of treatment, as evidenced by progression by RECIST 1.1; acquired resistance would be a subject who had a best overall RECIST response of stable disease, partial response, or complete response confirmed radiographically by a second scan who subsequently developed progressive disease by RECIST 1.1 at any time thereafter\"},\n                            {\"dose expansion part 2 sarcoma only: subjects must have received standard of care treatment\"}\n                        ]}\n                    ]\n                }\n            ]\n        },\n        {\n            \"$not\": {\n                \"$or\": [\n                    {\"chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\"},\n                    {\"less than 4 weeks post-operative (op) after major surgery\"},\n                    {\"currently participating in or have participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment\"},\n                    {\"diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\"},\n                    {\"prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier\"},\n                    {\"known additional malignancy that is progressing or requires active treatment\"},\n                    {\"lesions suspected to be at higher-risk for bleeding such as bowel involvement with tumor that invades into the bowel wall or involves the intraluminal component of bowel by imaging or direct visualization or central pulmonary lesions\"},\n                    {\"ulcerated skin lesions\"},\n                    {\"full anti-coagulant therapy Coumadin\"},\n                    {\"poorly-controlled hypertension as defined blood pressure (BP) greater than 150/100 mmHg, or systolic (S) BP greater than 180 mmHg when diastolic (D) BP less than 90 mmHg, on at least 2 repeated determinations on separate days within 3 months prior to study enrollment\"},\n                    {\"pregnant or nursing women\"},\n                    {\"known brain metastases\"},\n                    {\"carcinomatous meningitis\"},\n                    {\"previously treated brain metastases who are not stable, have evidence of new or enlarging brain metastases, or are using steroids for at least 7 days prior to trial treatment\"},\n                    {\"history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 and ziv-aflibercept\"},\n                    {\"active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents\"},\n                    {\"history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator\"},\n                    {\"known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\"},\n                    {\"received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or ziv-aflibercept\"},\n                    {\"uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\"},\n                    {\"pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\"},\n                    {\"human immunodeficiency virus (HIV) positive and do not meet the eligibility requirements\"},\n                    {\"known active hepatitis B or hepatitis C\"},\n                    {\"received a live vaccine within 30 days prior to the first dose of trial treatment\"},\n                    {\"history within 6 months prior to treatment of myocardial infarction, severe/unstable angina pectoris, coronary artery bypass graft (CABG), New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), stroke or transient ischemic attack (TIA)\"},\n                    {\"history within 3 months prior to treatment of grade 3-4 gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic event\"}\n                ]\n            }\n        }\n    ]\n}"}